uPA、uPAR与胃癌分期和预后

Both urokinase-type plasminogen activator (uPA) and its receptor (uPAR) relate to stage and prognosis of gastric carcinoma

目的 研究尿激酶型纤溶酶原激活物 (uPA)及其受体 (uPAR)与胃癌分期和预后的关系。方法 采用ELISA检测胃癌患者血浆、肿瘤、瘤旁和转移组织中uPA和uPAR ,与正常对照组血浆和组织比较。采用免疫组化方法检测肿瘤组织中 p5 3、nm2 3和CEA表达。结果 对照组血浆uPA和uPAR分别是 0 .6 5± 0 .2 1ng/ml和 0 .71± 0 .2 2ng/ml,胃组织中uPA和uPAR为 0 .71± 0 .33ng/ml和 0 .88± 0 .4 2ng/ml;而胃癌患者血浆uPA和uPAR分别是 1.98± 0 .4 1ng/ml和 2 .39± 0 .32ng/ml,癌组织uPA和uPAR是 2 .12± 0 .4 4ng/ml和 2 .6 8± 0 .4 0ng/ml,胃癌组血浆和肿瘤组织中uPA和uPAR均明显高于对照组 ,P<0 .0 5。uPA和uPAR在癌旁组织中为 1.14± 0 .32ng/ml和 1.30± 0 .4 1ng/ml,在癌转移灶中明显增高 ,分别是 3.6 3± 0 .77ng/ml和 4 .0 4± 0 .87ng/ml。血浆uPA和uPAR在低分化腺癌分别是 2 .5 7± 0 .38ng/ml和 3.38± 0 .4 7ng/ml比较其他病理类型 (乳头状、管状和黏液腺癌 ) 1.74± 0 .6 3ng/ml和 2 .0 6± 0 .4 3ng/ml明显升高 ,P <0 .0 5。血浆uPA和uPAR在I期胃癌接近正常对照值 ,为 0 .90± 0 .2 1ng/ml和 0 .99± 0 .34ng/ml ,II-IV期有递增趋势 ,IV期为 2 .78± 0 .2 7ng/ml和 3.12± 0 .31ng/ml,II-IV期与I期?

Objective To evaluate the relationship between uPA, uPAR, stage and prognosis of gastric carcinoma (GC). Methods Both uPA and uPAR were measured by ELISA in plasma, tumor extracts, paratumor and metastasis tissue in GC. The plasma of hernia and thyroid adenoma patients and the gastric tissue of benign ulcer were as control group. the p53,nm23 and CEA were detected in tumor by immunohistochemistry.Results In control group, uPA and uPAR were 0.65±0.21 ng/ml and 0.71±0.22 ng/ml in plasma, and 0.71±0.33 ng/ml and 0.88±0.42 ng/ml in gastric tissue respectively. In GC group, uPA and uPAR were 1.98±0.41 ng/ml and 2.39±0.32 ng/ml in plasma, and 2.12±0.44 ng/ml and 2.68±0.40 ng/ml in tumor tissue , compared to control respectively, P <0.05. uPA and uPAR were 1.14±0.32 ng/ml and 1.30±0.41 ng/ml in paratumor tissue, and 3.63±0.77 ng/ml and 4.04±0.87 ng/ml in metastasis lesion. Pathological type of low differentiation was higher than others type, they were 2.57±0.38 ng/ml and 3.38±0.47 ng/ml vs 1.74±0.63 ng/ml and 2.06±0.43 ng/ml, P <0.05 . In stage I of GC , uPA and uPAR were close to control group in plasma, they were 0.90±0.21 ng/ml and 0.99±0.34 ng/ml , moving up trend was showed from stage II to IV of GC. They were 2.78±0.27 ng/ml and 3.12±0.31 ng/ml in the stage IV of GC, compared with stage I, P <0.05. Thirty eight cases of GC were followed up: 5 years survival rate was 73.33% in stage I and II, 52.63% in stage III, 0% in stage IV. p53、nm23 and CEA have nothing to do with GC Stage .Conclusion Both uPA and uPAR were increased progressively according to GC staging. uPA and uPAR correlated closely in GC invasiveness, metastasis, poorly pathological kinds and prognosis.